These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 26991997

  • 1. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors.
    Liu Y, Yin Y, Zhang J, Nomie K, Zhang L, Yang D, Wang ML, Zhao G.
    Arch Pharm (Weinheim); 2016 May; 349(5):356-62. PubMed ID: 26991997
    [Abstract] [Full Text] [Related]

  • 2. Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity.
    Liu Y, Zhang Z, Ran F, Guo K, Chen X, Zhao G.
    Bioorg Chem; 2020 Apr; 97():103671. PubMed ID: 32120074
    [Abstract] [Full Text] [Related]

  • 3. Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity.
    Liu Y, Yin Y, Zhang Z, Li CJ, Zhang H, Zhang D, Jiang C, Nomie K, Zhang L, Wang ML, Zhao G.
    Eur J Med Chem; 2017 Sep 29; 138():543-551. PubMed ID: 28704757
    [Abstract] [Full Text] [Related]

  • 4. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX, Liu X, Xu S, Tang Q, Duan Y, Xiao Z, Zhi J, Jiang L, Zheng P, Zhu W.
    Eur J Med Chem; 2017 Dec 01; 141():538-551. PubMed ID: 29107421
    [Abstract] [Full Text] [Related]

  • 5. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.
    Addie M, Ballard P, Buttar D, Crafter C, Currie G, Davies BR, Debreczeni J, Dry H, Dudley P, Greenwood R, Johnson PD, Kettle JG, Lane C, Lamont G, Leach A, Luke RW, Morris J, Ogilvie D, Page K, Pass M, Pearson S, Ruston L.
    J Med Chem; 2013 Mar 14; 56(5):2059-73. PubMed ID: 23394218
    [Abstract] [Full Text] [Related]

  • 6. The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations.
    Xia Z, Huang R, Zhou X, Chai Y, Chen H, Ma L, Yu Q, Li Y, Li W, He Y.
    Eur J Med Chem; 2021 Nov 15; 224():113711. PubMed ID: 34315040
    [Abstract] [Full Text] [Related]

  • 7. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
    Wang R, Zhao X, Yu S, Chen Y, Cui H, Wu T, Hao C, Zhao D, Cheng M.
    Bioorg Chem; 2020 Sep 15; 102():104092. PubMed ID: 32707280
    [Abstract] [Full Text] [Related]

  • 8. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W, Wang W, Xu S, Wang J, Tang Q, Wu C, Zhao Y, Zheng P.
    Bioorg Med Chem; 2016 Apr 15; 24(8):1749-56. PubMed ID: 26964675
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
    Wang R, Chen Y, Zhao X, Yu S, Yang B, Wu T, Guo J, Hao C, Zhao D, Cheng M.
    Eur J Med Chem; 2019 Dec 01; 183():111716. PubMed ID: 31550660
    [Abstract] [Full Text] [Related]

  • 10. Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.
    Lee JH, El-Damasy AK, Seo SH, Gadhe CG, Pae AN, Jeong N, Hong SS, Keum G.
    Bioorg Med Chem; 2018 Nov 15; 26(21):5596-5611. PubMed ID: 30385226
    [Abstract] [Full Text] [Related]

  • 11. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidine derivatives containing 1,8-naphthyridine-4-one fragment.
    Zhang J, Chen P, Duan Y, Xiong H, Li H, Zeng Y, Liang G, Tang Q, Wu D.
    Eur J Med Chem; 2021 Apr 05; 215():113273. PubMed ID: 33601310
    [Abstract] [Full Text] [Related]

  • 12. Discovery of pyrrolopyrimidine inhibitors of Akt.
    Blake JF, Kallan NC, Xiao D, Xu R, Bencsik JR, Skelton NJ, Spencer KL, Mitchell IS, Woessner RD, Gloor SL, Risom T, Gross SD, Martinson M, Morales TH, Vigers GP, Brandhuber BJ.
    Bioorg Med Chem Lett; 2010 Oct 01; 20(19):5607-12. PubMed ID: 20810279
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
    Gangjee A, Namjoshi OA, Yu J, Ihnat MA, Thorpe JE, Warnke LA.
    Bioorg Med Chem; 2008 May 15; 16(10):5514-28. PubMed ID: 18467105
    [Abstract] [Full Text] [Related]

  • 14. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
    Wang Y, Liu WJ, Yin L, Li H, Chen ZH, Zhu DX, Song XQ, Cheng ZZ, Song P, Wang Z, Li ZG.
    Bioorg Med Chem Lett; 2018 Mar 01; 28(5):974-978. PubMed ID: 29429832
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W, Wang W, Xu S, Tang Q, Luo R, Wang M, Gong P, Zheng P.
    Bioorg Med Chem; 2016 Feb 15; 24(4):812-9. PubMed ID: 26810712
    [Abstract] [Full Text] [Related]

  • 16. Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line.
    Jung MH, Kim H, Choi WK, El-Gamal MI, Park JH, Yoo KH, Sim TB, Lee SH, Baek D, Hah JM, Cho JH, Oh CH.
    Bioorg Med Chem Lett; 2009 Dec 01; 19(23):6538-43. PubMed ID: 19857963
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
    Shi X, Quan Y, Wang Y, Wang Y, Li Y.
    Bioorg Med Chem Lett; 2021 Feb 01; 33():127725. PubMed ID: 33316409
    [Abstract] [Full Text] [Related]

  • 18. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Wang L, Liu X, Duan Y, Li X, Zhao B, Wang C, Xiao Z, Zheng P, Tang Q, Zhu W.
    Chem Biol Drug Des; 2018 Jul 01; 92(1):1301-1314. PubMed ID: 29575727
    [Abstract] [Full Text] [Related]

  • 19. Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).
    McHardy T, Caldwell JJ, Cheung KM, Hunter LJ, Taylor K, Rowlands M, Ruddle R, Henley A, de Haven Brandon A, Valenti M, Davies TG, Fazal L, Seavers L, Raynaud FI, Eccles SA, Aherne GW, Garrett MD, Collins I.
    J Med Chem; 2010 Mar 11; 53(5):2239-49. PubMed ID: 20151677
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents.
    Tan H, Liu Y, Gong C, Zhang J, Huang J, Zhang Q.
    Eur J Med Chem; 2021 Nov 05; 223():113670. PubMed ID: 34214842
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.